© 2009 Swords et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Drug Design, Development and Therapy 2009:3 89–101 89

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

ROSTI, GIANANTONIO
CASTAGNETTI, FAUSTO
GUGLIOTTA, GABRIELE
PALANDRI, FRANCESCA
BACCARANI, MICHELE

January 2012

Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding a...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Martinelli G.
Iacobucci I.
Soverini S.
Palandri F.
Castagnetti F.
Rosti G.
Baccarani M.

January 2007

Although high rates of complete hematologic and cytogenetic remission have been observed in patients...

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

Giuliana Alimena
Massimo Breccia

October 2008

Massimo Breccia, Giuliana AlimenaDepartment of Cellular Biotechnology and Hematology, &ldquo;Sap...

That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia

Ann Dermatol
Dysplastic Nevus
Eruptive Melanocytic Lesions
Joo Hyun Lee
Jin Hee Kang
Baik Kee Cho
Hyun Jeong Park

January 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-C...

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia

Hassan A. Al-jafar
Hassan A. Al-jafara
Ali Al-mullab
Salma Aldallala
Jaber H. Buhamadc

January 2015

NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online ...

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Ronan Swords
Devalingam Mahalingam
Swaminathan Padmanabhan
Jennifer Carew
Francis Giles

March 2009

Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis GilesInstitute...

Management of chronic Myeloid Leukemia with BcR/ABL Inhibitors: current status and Future perspectives

Peter Valent

October 2016

Review Article Imatinib in Chronic Myeloid Leukemia: an Overview

Tomasz Sacha

January 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Lice...

Review Article Imatinib in Chronic Myeloid Leukemia: an Overview

Tomasz Sacha

January 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

July 2015

none5Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and bind...

article which permits unrestricted noncommercial use, provided the original work is properly cited. Journal of Blood Medicine 2012:3 139–150 Journal of Blood Medicine

Yusuf Baran
Guray Saydam
Correspondence Yusuf Baran

August 2016

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic mye...

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

ROSTI, GIANANTONIO
CASTAGNETTI, FAUSTO
GUGLIOTTA, GABRIELE
PALANDRI, FRANCESCA
BACCARANI, MICHELE

January 2012

Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding a...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Martinelli G.
Iacobucci I.
Soverini S.
Palandri F.
Castagnetti F.
Rosti G.
Baccarani M.

January 2007

Although high rates of complete hematologic and cytogenetic remission have been observed in patients...

equally to this article.

Philadelphia Chromosome–positive All
Oliver G. Ottmann
Fakultät Klinische
Medizin Mannheim
Drs Kantarjian
Giles Contributed
N Engl
J Med

July 2015

Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitr...

© 2013 Hohenforst-Schmidt et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Drug Design, Development and Therapy 2013:7 571–583

Kaid Darwiche
Thomas Vogl
Eugene P Goldberg
Haidong Huang
Michael Simoff
Qiang Li
Robert Browning
Francis J Turner
Patrick Le Pivert
Dionysios Spyratos
Konstantinos Zarogoulidis
Seyhan I Celikoglu
Firuz Celikoglu
Johannes Brachmann
Department-oncology Unit
G Papanikolaou
Interventional Pulmonology
Critical Care Medicine

September 2016

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies Wolfgang Hohenfor...

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

ROSTI, GIANANTONIO
CASTAGNETTI, FAUSTO
GUGLIOTTA, GABRIELE
PALANDRI, FRANCESCA
BACCARANI, MICHELE

January 2012

Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding a...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Martinelli G.
Iacobucci I.
Soverini S.
Palandri F.
Castagnetti F.
Rosti G.
Baccarani M.

January 2007

Although high rates of complete hematologic and cytogenetic remission have been observed in patients...

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

Giuliana Alimena
Massimo Breccia

October 2008

Massimo Breccia, Giuliana AlimenaDepartment of Cellular Biotechnology and Hematology, &ldquo;Sap...

That Developed during Nilotinib Therapy for Chronic Myeloid Leukemia

Ann Dermatol
Dysplastic Nevus
Eruptive Melanocytic Lesions
Joo Hyun Lee
Jin Hee Kang
Baik Kee Cho
Hyun Jeong Park

January 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-C...

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia

Hassan A. Al-jafar
Hassan A. Al-jafara
Ali Al-mullab
Salma Aldallala
Jaber H. Buhamadc

January 2015

NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online ...

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Ronan Swords
Devalingam Mahalingam
Swaminathan Padmanabhan
Jennifer Carew
Francis Giles

March 2009

Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis GilesInstitute...

Management of chronic Myeloid Leukemia with BcR/ABL Inhibitors: current status and Future perspectives

Peter Valent

October 2016

Review Article Imatinib in Chronic Myeloid Leukemia: an Overview

Tomasz Sacha

January 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Lice...

Review Article Imatinib in Chronic Myeloid Leukemia: an Overview

Tomasz Sacha

January 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licen...

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

July 2015

none5Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and bind...

article which permits unrestricted noncommercial use, provided the original work is properly cited. Journal of Blood Medicine 2012:3 139–150 Journal of Blood Medicine

Yusuf Baran
Guray Saydam
Correspondence Yusuf Baran

August 2016

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic mye...

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

ROSTI, GIANANTONIO
CASTAGNETTI, FAUSTO
GUGLIOTTA, GABRIELE
PALANDRI, FRANCESCA
BACCARANI, MICHELE

January 2012

Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding a...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Martinelli G.
Iacobucci I.
Soverini S.
Palandri F.
Castagnetti F.
Rosti G.
Baccarani M.

January 2007

Although high rates of complete hematologic and cytogenetic remission have been observed in patients...

equally to this article.

Philadelphia Chromosome–positive All
Oliver G. Ottmann
Fakultät Klinische
Medizin Mannheim
Drs Kantarjian
Giles Contributed
N Engl
J Med

July 2015

Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitr...

© 2013 Hohenforst-Schmidt et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Drug Design, Development and Therapy 2013:7 571–583

Kaid Darwiche
Thomas Vogl
Eugene P Goldberg
Haidong Huang
Michael Simoff
Qiang Li
Robert Browning
Francis J Turner
Patrick Le Pivert
Dionysios Spyratos
Konstantinos Zarogoulidis
Seyhan I Celikoglu
Firuz Celikoglu
Johannes Brachmann
Department-oncology Unit
G Papanikolaou
Interventional Pulmonology
Critical Care Medicine

September 2016

Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies Wolfgang Hohenfor...

Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML

ROSTI, GIANANTONIO
CASTAGNETTI, FAUSTO
GUGLIOTTA, GABRIELE
PALANDRI, FRANCESCA
BACCARANI, MICHELE

January 2012

Nilotinib is a rationally designed tyrosine kinase inhibitor with improved specificity and binding a...

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Martinelli G.
Iacobucci I.
Soverini S.
Palandri F.
Castagnetti F.
Rosti G.
Baccarani M.

January 2007

Although high rates of complete hematologic and cytogenetic remission have been observed in patients...

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib

Giuliana Alimena
Massimo Breccia

October 2008

Massimo Breccia, Giuliana AlimenaDepartment of Cellular Biotechnology and Hematology, &ldquo;Sap...

© 2009 Swords et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Drug Design, Development and Therapy 2009:3 89–101 89

Abstract

Extracted data

© 2009 Swords et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Drug Design, Development and Therapy 2009:3 89–101 89

Abstract

Extracted data

Related items

Related items